Jeffrey Bryan DVM, MS, PhD
Diplomate ACVIM
bryanjn@vetmed.wsu.edu
Assistant Professor
DVM University of California, Davis, 1993
MS University of Missouri-Columbia, 2004
PhD University of Missouri-Columbia, 2007
Residency in Medical Oncology, University of Missouri-Columbia, 2002-2005
National Library of Medicine Post-doctoral Fellowship in Bioinformatics,
University of Missouri-Columbia, 2005-2007
Diplomate of the American College of Veterinary Medicine, Specialty
Oncology
Research Interests
Dr. Bryan is committed to improving the oncology care of companion
animals as well as studying animal cancers as
models for human disease. Dr. Bryan is currently studying the epigenetic
alterations present in canine lymphoma, evaluating the epidemiology of
canine cancers, and developing radiopharmaceutical imaging and therapy
agents for cancer.
Publications
Bryan JN, Keeler MR, Henry CJ, Bryan ME, Hahn AW, Caldwell CW. A
population study of neutering status as a risk factor for canine prostate
cancer, The Prostate. In Press
McCaw DL, Chan AS, Stegner AL, Mooney B, Bryan JN, Turnquist SE, Henry
CJ, Alexander H, Alexander S. Proteomics of canine lymphoma identifies
potential cancer specific protein markers, Clin Cancer Res. In Press.
Suedmeyer WK, Bryan JN, Johnson G, Freeman A. Excision of multiple
chromatophoromas in an eastern yellowbelly racer. J Zoo Wildl Med. 2007;
38(1): 127-130.
Bryan JN, Henry C , Turnquist S, Tyler J, Liptak J, Rizzo S, Sfiligoi G,
Steinberg H, Smith A, Jackson T. Primary renal neoplasia of dogs: a
retrospective review of 82 cases. J Vet Intern Med, 2006; 20:1155-1160.
Bryan JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ,
and Lewis MR. Comparative uptakes and biodistributions of internalizing
versus non-internalizing copper-64 radioimmunoconjugates in cell and animal
models of colon cancer. Nucl Med Biol, 2005; 32(8): 851-858.
Henry CJ, Buss MS, Hellström I, Hellström KE, Bryan JN, Brewer WG, and
Siegall CB. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in
canine models of spontaneously occurring invasive carcinoma. Clin Cancer
Res, 2005; 11(2 Pt 1):751-55.
Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru
G, Anderson CJ. Development of a two-antibody model for the evaluation of
copper-64 radioimmunotherapy. Veterinary and Comparative Oncology 2004;
2(2):82-90.
